GSK525762

DRUG4 trials

Sponsors

GlaxoSmithKline

Conditions

Carcinoma, MidlineNeoplasmsSolid Tumours

Phase 1

A Study to Investigate the Safety, Pharmacokinetics, Pharmacodynamics, and Clinical Activity of GSK525762 in Subjects With NUT Midline Carcinoma (NMC) and Other Cancers

CompletedNCT01587703

GlaxoSmithKlineCarcinoma, Midline

Start: 2012-03-28End: 2019-07-29Updated: 2020-03-16

Dose Escalation and Expansion Study of GSK525762 in Combination With Fulvestrant in Participants With Hormone Receptor-positive (HR+)/Human Epidermal Growth Factor Receptor 2 Negative (HER2-) Advanced or Metastatic Breast Cancer

TerminatedNCT02964507

GlaxoSmithKlineNeoplasms

Start: 2019-09-26End: 2021-07-19Updated: 2024-08-29

Dose Escalation and Dose Expansion Study of GSK525762 in Combination With Androgen Deprivation Therapy in Participants With Castrate-resistant Prostate Cancer

TerminatedNCT03150056

GlaxoSmithKlineSolid Tumours

Start: 2017-07-18End: 2021-06-22Updated: 2022-08-10

Phase 2

A Dose Escalation Study to Investigate the Safety, Pharmacokinetics (PK), Pharmacodynamics (PD) and Clinical Activity of GSK525762 in Subjects With Relapsed, Refractory Hematologic Malignancies

CompletedNCT01943851

GlaxoSmithKlineNeoplasms

Start: 2014-05-14End: 2020-04-30Updated: 2024-10-01

Related Papers

Clinical outcomes and correlation with longitudinal circulating tumor (ct)DNA dynamics of a phase I/II study of GSK525762 combined with fulvestrant in patients with hormone receptor-positive/HER2-negative (HR+/HER2−) advanced or metastatic breast cancer.

Journal of Clinical Oncology2023-06-01

A Phase I/II Open-Label Study of Molibresib for the Treatment of Relapsed/Refractory Hematologic Malignancies

Clinical Cancer Research2022-11-0930 citations

BET inhibitor molibresib for the treatment of advanced solid tumors: Final results from an open-label phase I/II study.

Journal of Clinical Oncology2020-05-207 citations

A phase Ib open-label, dose escalation and expansion study to investigate the safety, pharmacokinetics, pharmacodynamics and clinical activity of GSK525762 in combination with abiraterone or enzalutamide in metastatic castrate-resistant prostate cancer.

Journal of Clinical Oncology2018-02-206 citations

Abstract OT3-06-07: A phase I/II dose escalation and expansion study to investigate the safety, pharmacokinetics, pharmacodynamics and clinical activity of GSK525762 in combination with fulvestrant in subjects with ER+ breast cancer

Cancer Research2018-02-151 citations

Abstract CT104: A first-in-human phase I dose escalation study of BET inhibitor GSK2820151 in patients with advanced or recurrent solid tumors cancers

Cancer Research2017-07-014 citations

A phase I/II dose escalation and expansion study to investigate the safety, pharmacokinetics, pharmacodynamics and clinical activity of GSK525762 in combination with fulvestrant in subjects with ER+ breast cancer.

Journal of Clinical Oncology2017-05-204 citations

The bromodomain inhibitor OTX015 (MK-8628) exerts anti-tumor activity in triple-negative breast cancer models as single agent and in combination with everolimus

Oncotarget2016-12-0792 citations

Abstract CT014: GSK525762, a selective bromodomain (BRD) and extra terminal protein (BET) inhibitor: results from part 1 of a phase I/II open-label single-agent study in patients with NUT midline carcinoma (NMC) and other cancers

Cancer Research2016-07-1537 citations

NUT midline carcinoma: an aggressive intrathoracic neoplasm.

2013-10-0137 citations